Sign up for free to receive the latest news straight to your inbox
The new chairman of pharmaceutical company Burton Clinigen was revealed this morning (September 1).
Peter Allen will leave the company and will be replaced as President by Elmar Schnee.
Schnee has recently served on the board of directors of Jazz Pharmaceuticals, since 2014. He works as a non-executive director on several other boards of directors of pharmaceutical companies, including Santhera AG and Calliditas AB, alongside several others. private biopharmaceutical companies.
Shaun Chilton, President and CEO of Clinigen, said: “I would like to thank Peter on behalf of the board and personally for his leadership and valuable contributions since Clinigen IPO in 2012. I appreciated to work with Elmar to this day and look forward to working more closely with him as we continue to grow the business and create value.
Schnee said: “Clinigen has built a strong global business that is uniquely positioned to provide end-to-end service to pharmaceutical customers. I look forward to continuing to work with the board and management as we build on the company’s successes to date and realize the full potential of its lifecycle platform.
Allen added, “I am proud to have spent nine years as President of Clinigen. During this time, the company has grown and become a global leader in providing global access to medicines, delivering significant value to patients, customers and shareholders. I have every confidence in Clinigen’s continued success.